History
Trazapentin®
Astrapharm introduced Trazapentin®, an innovative centrally acting analgesic for cats and dogs. The formulation combines trazodone and gabapentin, offering a comprehensive approach to pain management.
Trazapentin is indicated for:
- chronic neuropathic pain,
- multimodal analgesia protocols,
- pre- and postoperative therapy,
- anxiety-related pain syndromes.
The product effectively reduces pain sensitivity, improves the quality of life for animals, and is suitable for use both in veterinary clinics and at-home care settings.
Firocoxib-ASTRA
Astrapharm introduced Firocoxib-ASTRA®, a nonsteroidal anti-inflammatory drug (NSAID) designed to relieve pain and inflammation in dogs. The active ingredient, firocoxib, is a selective cyclooxygenase-2 (COX-2) inhibitor that provides potent analgesic and anti-inflammatory effects with a high safety profile.
The product is indicated for:
- pain relief in osteoarthritis,
- perioperative analgesia,
- and use during the rehabilitation period.
Firocoxib-ASTRA is well-tolerated and suitable for both short-term and long-term therapy in dogs of various breeds and ages. Its convenient tablet form enhances treatment compliance and ease of administration.
FORSECTO®
Astrapharm launched the innovative ectoparasiticide FORSECTO® for the protection of cats and dogs against external parasites. Its unique, patented formula — combining tebufenpyrad and ethofenprox — delivers a powerful knockdown effect, killing parasites before they bite.
FORSECTO provides effective protection against:
- ticks (up to 12 weeks),
- fleas (up to 16 weeks),
- mosquitoes (up to 10 days).
The product acts on all life stages of parasites and does not cause resistance, making it more effective than conventional treatments.
Its convenient single-dose pipette with an easy-break nozzle allows quick and precise application without stress for the pet. The formula has a mild, pleasant scent, ensuring a comfortable experience for both animals and owners.
A single pack containing two pipettes provides season-long protection with no need for reapplication.
Confirmation of High Quality Standards in Product Manufacturing
Astrapharm has once again obtained the Certificate of Compliance for the manufacturing of medicinal products with the Good Manufacturing Practice (GMP) Rules of the Eurasian Economic Union.
This achievement highlights the company’s stability, its commitment to high production standards, and the successful regulation of technological processes, ensuring the conditions necessary for the manufacturing of high-quality veterinary pharmaceuticals.
Course Trazadex®
Astrapharm introduced Course Trazadex®, a medication for gentle and long-term behavioral correction in cats and dogs. It is used in stressful situations, behavioral disturbances, and during periods of sexual activity — without affecting reproductive function.
The product is effective in:
- periods of separation from the owner;
- postoperative care or hospitalization;
- adult and senior animals to improve quality of life;
- behavioral issues related to mating behavior.
Course Trazadex does not cause dependence and provides sustained remission even after discontinuation. It can be used in combination with behavior therapy or canine training.
The product comes in meat-flavored tablets, making administration easy and reducing stress for both pets and owners.
Course Trazadex offers up to 24 hours of action with twice-daily dosing, ensuring stable behavioral support throughout the treatment course.
Launch of Supramil® in Emulsion Form
Astrapharm introduced the innovative anthelmintic Supramil® in a new liquid emulsion form, providing precise dosing, convenient administration, and high palatability.
Supramil effectively eliminates roundworms and tapeworms and is used for the prevention of dirofilariasis. Its stable, homogeneous emulsion requires no shaking prior to use.
The product is recommended for:
- cats and dogs of all breeds,
- kittens over 6 weeks old, and puppies older than 2 weeks,
- pregnant and lactating animals.
The convenient syringe-doser ensures stress-free administration, even for the most finicky pets. Its pet-friendly flavor has been proven palatable in feed acceptance studies.
A single dose provides both treatment and prevention of helminth infections, making Supramil the optimal choice for caring pet owners.
Obtaining the Certificate of Good Manufacturing Practices (GMP) Compliance of Veterinary Medicinal Product Manufacturers in Turkey
In February 2023, Astrapharm once again demonstrated its commitment to the highest standards of veterinary pharmaceutical manufacturing by successfully passing an international GMP inspection. The inspection was conducted under the national inspection program of the Ministry of Agriculture and Forestry of the Republic of Turkey, in accordance with Article 79 of the Regulation on Veterinary Medicinal Products.
Following this audit, Astrapharm was officially recognized as being fully compliant with the principles and guidelines of Good Manufacturing Practice (GMP).
This certificate reaffirms Astrapharm’s position as a trusted manufacturer of veterinary medicinal products that meet strict international standards for safety, quality, and efficacy.
Adherence to GMP is a cornerstone of our strategy — ensuring not only the confidence of veterinarians and pet owners, but also enabling us to expand into new markets and strengthen our global presence.
Obtaining the Certificate of Compliance with GMP Requirements of the Eurasian Economic Union
In December 2022, the Astrapharm reaffirmed its commitment to the highest quality standards by obtaining the Certificate of Compliance for the manufacturer of veterinary medicinal products with the Good Manufacturing Practice (GMP) Rules of the Eurasian Economic Union, No. GMP-83/22. The certificate was issued by the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor).
The issuance of this GMP certificate confirms Astrapharm's dedication to providing consumers with affordable, high-quality, effective, and safe veterinary medicinal products. Meeting quality requirements is considered a key condition for expanding market presence, increasing profitability, growing production volumes, and driving the company’s overall development.
Receiving the GMP certificate has strengthened Astrapharm's reputation, enhanced its competitiveness in the veterinary market, and opened up significant opportunities for exporting its products beyond national borders.
BlohNet Forte: Your Power Against External Parasites
The launch of the product BlohNet Forte. BlohNet Forte became a breakthrough in 2022 in the insectoacaricidal product segment. The secret to BlohNet Forte’s success lies in its enhanced active formula and ultra-convenient application form.
The product is available as spot-on drops applied to the withers in a single-dose pipette. Simply choose the packaging according to the species and weight of your pet, and treat accordingly.
Thanks to its reinforced active formula, the product provides long-lasting protection for cats and dogs against external parasites:
- against ixodid ticks — up to 35 days,
- against fleas, lice, and chewing lice — up to 56 days,
- repels mosquitoes — up to 7 days.
These results are supported by years of product research across various parasite-related issues.
Despite its powerful protection, BlohNet Forte maintains a high safety profile. It does not enter the bloodstream and does not cause allergies or irritation. BlohNet Forte is classified as hazard class IV — the lowest level of toxicity.
The product was developed with the support of the Foundation for Assistance to Small Innovative Enterprises in Science and Technology.
The GMP Certificate of the Eurasian Economic Union
In May 2021, Astrapharm obtained the Certificate of Compliance with the Rules of Good Manufacturing Practice of the Eurasian Economic Union No. GMP/TAEU/RU/00089-2021 (GMP – Good Manufacturing Practice Certificate). This certificate is issued by the Ministry of Industry and Trade following a pharmaceutical inspection, during which it was confirmed that Astrapharm fully complies with the requirements of the EAEU Good Manufacturing Practice Rules for the production of medicinal products for human use.
Supramil. A superpill for a superpet.
Launch of the drug Supramil. Supramil is an anthelmintic drug with incredible eatability. The tablets have a special shell with a meat taste.
The drug destroys tape and round helminths at all stages of their development, as well as Dirofilaria larvae.
The study results demonstrated that all animals participating in the experiment were 100% cured of helminthiasis after the first use of Supramil.
Advanced technologies used in the development of anthelmintic drugs have significantly improved the safety profile of Supramil compared to any other anthelmintic pill. Supramil has a unique proprietary formulation: R-praziquantel and milbemycin oxime.
Dogferon® — the first Russian injectable canine interferon preparation (alpha-interferon of canine origin).
The product is used to treat parvoviral enteritis, viral hepatitis, parainfluenza, and other viral infections in both puppies and adult dogs. In severe clinical cases, the dosage may be doubled.
Dogferon has a dual mechanism of action — antiviral and immunostimulatory. It activates intracellular enzymes (oligo-adenylate cyclase, protein kinase, and translation initiation factor), leading to interferon-dependent suppression of viral replication at the translation stage. It also induces the expression of genes responsible for cellular antiviral defense.
Clinical studies have shown that puppies with parvoviral enteritis treated with Dogferon demonstrated notable clinical improvement by day 5 of treatment compared to the control group, indicating rapid recovery and reduced disease duration.
Express Uspokoin. To quickly overcome anxiety and stress.
Launch of the drug Express Uspokoin. The market success of Express Uspokoin derives from being an excellent drug that solves the behavioral problems of cats and dogs in stressful situations quickly and after the first use.
The premium formulation takes effect within 30 minutes after the administration and helps to cope with stress in animals in any situation. Express Uspokoin tablets are coated with a meat-flavored coating attractive for the animals. The action of the drug lasts for 6-8 hours.
Express Uspokoin confidently solves the behavioral problems of animals because of its composition. The preparation contains the active ingredient succinate trazodone which is an original patented project.
The Loan from Moscow Fund for support of Industry and Entrepreneurship
The Moscow Fund for support of Industry and Entrepreneurship issued the first soft loan to LLC “Astrapharm”. The company approved a loan in the amount of 50 million rubles for the implementation of the project, the cost of which is 71.8 million rubles.
A loan was provided for the purchase of manufacturing and laboratory equipment to increase sales of products and fill the market with domestic competitive veterinary drugs. Implementation of the project will lead to the expansion and automation of the production capacities of LLC “Astrapharm”. This will increase the Company's turnover and lead to an increase in the supply of drugs for pets.
LLC "SIE Astrapharm" will receive funds for a period of 5 years at a rate of 5% per annum, while the terms of the transaction provide for a deferment of payment of the principal debt amount for a period of 24 months.
As collateral, the Company provided its own equipment and vehicles in the amount of 30% of the principal debt.
The remaining 70% is secured by the guarantee of the Fund of Small Business Credit Assistance of Moscow, the cost of which for the borrower is only 0.75% per annum.
The loan was approved as part of the Program “product Industry" for residents of the special economic zone (SEZ) of Moscow, participants in innovation clusters, residents and management companies of technology parks (industrial parks).
TechSuccess 2016
Within the framework of the III Congress “Innovation Practice: Science plus Business”, LLC "SIE Astrapharm" was declared the laureate of the annual National Rating of the Russian high technology fast-growing companies "TechSuccess-2016” in the category of small companies.
Rating “TechSuccess-2016” was organized by RVC in partnership with the Higher School of Economics and PwC and has been held since 2012. The rating is an authoritative and effective tool for finding, monitoring and promoting promising fast-growing technology companies, which in the future should play a key role in the development and modernization of Russian technology industries.
That is why in 2016 TechSuccess was chosen as the basis for the priority project of the Ministry of Economic Development “Support for private high-tech leading companies” (“National Champions”), aimed at providing focused support to companies in various industries that have significant potential to gain domestic and foreign markets.
Leader of Russia 2016
LLC "SIE Astrapharm" was awarded the title of “Leader of Russia”. This award is given by the Union of National Business Ratings to business entities for significant economic achievements, maintaining high standards of social protection of employees, the introduction of innovative technologies, as well as for a worthy contribution to the development of the industry.
According to the results of the national financial and economic analysis of the activities of the Russian Federation enterprises in the field of healthcare, LLC "SIE Astrapharm" has received:
- Gold in the rating among enterprises of the Russian Federation in the nomination "Indicators of resource use efficiency";
- Gold in the rating among Moscow enterprises by the sum of 3th categories of financial and economic activities.
TechSuccess 2015
On October 28, 2015, at the Moscow International Forum “Open Innovations”, the winners of the fourth national rating TechSuccess of Russian high-tech fast-growing companies were announced. LLC "SIE Astrapharm" was declared a laureate of the National rating of Russian high-tech fast-growing companies “TechSuccess-2015”. The company entered the TOP 10 fast-growing companies.
The annual rating TechSuccess is organized by RVC in partnership with PwC, which developed the rating methodology, SME Bank and HSE. During its existence, the Rating has established itself as an effective tool for searching, monitoring and promoting promising fast-growing companies in the Russian Federation that have a high potential for leadership in the market.
When compiling the rating, unique information was collected on more than a hundred domestic technology companies. The rating includes only enterprises and organizations that have consistently demonstrated over the past few years indicators above the industry average.
Feliferon® — the first Russian injectable feline interferon (omega-interferon) preparation
Feliferon is used for therapeutic and preventive purposes in viral and mixed infections in cats, including gastroenteritis, acute respiratory diseases, herpesvirus, calicivirus, panleukopenia, and others.
The product has a dual mechanism of action — antiviral and immunostimulatory. It suppresses the replication of DNA- and RNA-containing viruses, activates macrophages, and enhances the specific cytotoxic activity of lymphocytes.
Feliferon contributes to faster recovery: as early as after the first dose, normalization of body temperature, respiration, and heart rate is observed. When used as part of combination therapy, it ensures a stable and positive clinical progression of the disease.
TechSuccess 2013
During the round table “TechSucces 2013: Russian Potential in Action” at the “Open Innovations” forum, the results of the second national rating of Russian high-tech fast-growing companies were announced. According to the results of the rating, LLC "SIE Astrapharm" entered the TOP-30 of the most dynamically developing companies in Russia, focused on innovation and technology development, showing stable results over the past three years that are above average in their industry. An important evaluation criterion was the requirement for the successful market release of at least one new product or service based on the company's own intellectual developments.
The company is in permanent pursuit of perfection: it conducts active R&D in the field of veterinary medicine in cooperation with the Moscow Fund of support of the industry and entrepreneurship in the scientific and technical field. The goal of the LLC "SIE Astrapharm" is the continuous improvement of all stages of the enterprise and reaching new heights in the development and manufacturing of therapeutic and prevention drugs for animals.
IN-AP complex in the new packaging
Pack renewal of the unique drug IN-AP complex, which solves the problem of ectoparasites infection and helminths at the same time. Updated packaging design allows pet owners to quickly find the right product for their pet.
Gestrenol in the new packaging
Market launch of the drug “Gestrenol” for the regulation of sexual hunt in female and male cats in an updated package. Packaging design has become more vivid and informative. Thanks to color solutions, it accurately conveys the purpose of the drug by sexual character. This facilitates the choice of the buyer in the pet store.
Updating the packaging of the drug bottle: the bottle is packaged in a blister, which provides reliable protection of the contents from external influences and guarantees the owner the purchase of the original drug.
BlochNet update
BlochNet, a well-known on the market insecticidal-acaricidal drug, was updated. The product received a new name “BlochNet max”, its effectiveness has been increased, the packaging design has become more attractive to customers.
The new enhanced formula of the drug, based on fipronil, with the addition of a substance “Yuvemon”, which was developed by LLC “Astrapharm”, reliably protects the pet from ectoparasites of all types and significantly reduces the risk of re-infection, as it destroys their eggs and larvae.
Cooperation with the Fund of Small Business Credit Assistance
LLC “SIE Astrapharm” won the Fund competition and entered into a state contract for the development of recombinant vaccine technology.
Thanks to cooperation with the Fund, LLC "SIE Astrapharm" acquired its own manufactoring base, and hi-tech equipment was purchased, including an analytical laboratory. As for the new drug, a fundamentally new approach to contraception was implemented in it.
KontrSex Neo: everything is under control
Launch of the drug “KontrSex Neo” in the form of drops and tablets for the regulation of sexual hunt in cats and dogs. KontrSex Neo is affordable for prevention of sexual excitement, regulation of hunt, correction of unwanted behavior in female cats and dogs and male cats and dogs The owner of the pet has the opportunity to choose the most convenient form of the drug - drops or tablets.
Unique drug IN-AP complex
Market launch of the drug “IN-AP complex”. The drug was a real discovery for pet owners. This unique product quickly won its customer in the market. The veterinary drug has gained high popularity among owners of cats and dogs due to the possibility of its complex use against ectoparasites (fleas, ixodid ticks, lice and Trichodectidae) and helminths (round and tapeworms). "IN-AP complex" is a unique drug that has no analogues in its properties among Russian and foreign brands.
Gestrenol - specifically for cats
Market launch of the drug "Gestrenol drops” for the regulation of sexual hunt. The drug was developed specifically for female and male cats, taking into account the characteristics of these animals. Many owners appreciate Gestrenol for the convenient form of the drug and the guaranteed effectiveness of solving animal problems.
BlokhNet Spray
Expansion of a product line “BlokhNet” was realized by launching on the market the “BlokhNet spray” against fleas and ticks. It is convenient to use and is widely used for the effective treatment of both animals themselves and their places of keeping.
Competition “Export”
LLC "SIE Astrapharm" won the competition “Export” of the Fund for assistance to the development of small forms of enterprises in the scientific and technical field. This made it possible to create a research and manufacturing site. One of the results of the work is the creation of a unique drug “IN-AP complex”.
Modern protection against ticks and fleas
The expanding a product line “BlokhNet” was realized by launching on the market the “BlokhNet spray” against fleas and ticks. It is convenient to use and is widely used for the effective treatment of both animals themselves and their places of keeping.
Vermidin – the drug with affordable quality
Market launch of a broad-spectrum anthelmintic drug “Vermidin”. Over the years of its existence in the domestic market, the drug has proven to be a universal and safe tool.
Company creation
The Scientific and Implementation Enterprise “Astrapharm” was founded in 2002 to develop and organize manufacturing of treatment and prevention drugs for animals.
The Scientific and Implementation Enterprise “Astrapharm” uses the developments of research institutes, highly qualified specialists, and scientific personnel. Thanks to this, the company managed to create and place on the market a number of innovative products. The company uses a modern approach to doing business, a marketing approach to the development and implementation of drugs. This allows it to produce high-quality products which are demanded on the market.
